BID and acute lymphoblastic leukemia: In addition, CD7 CARCD7-T-cells demonstrated in vivo persistence and protection of NGS mice receiving 1×104 CCRF (T-ALL) or 3×106 BV173 (B-ALL) cells from tumor relapse.